Pasithea Therapeutics Corp. (KTTAW)

Pasithea Therapeutics Corporation is an early-stage biotech firm at the intersection of central nervous system biology, oncology, and rare genetic disease. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida, trading on NASDAQ under the symbols KTTA for common stock and KTTAW for warrants. Pasithea’s strategy is to identify and develop next-generation small-molecule drugs targeting specific molecular pathways implicated in severe, underserved disease areas — chiefly conditions driven by mutations in the RAS/MAPK signaling cascade and selected central nervous system disorders.

The lead program: PAS-004 for RASopathies and MAPK-driven cancers.

Pasithea’s most advanced product candidate is PAS-004, a macrocyclic mitogen-activated protein kinase (MEK) inhibitor designed to address a class of genetic diseases caused by hyperactivation of the RAS pathway. The lead indication is neurofibromatosis type 1 (NF1), a genetic disorder characterized by the growth of benign tumors along the nervous system. NF1 patients with plexiform neurofibromas — large, disabling tumors formed from nerve sheaths — have limited therapeutic options beyond surgical removal. PAS-004 targets the molecular driver of those tumors by inhibiting downstream RAS signaling.

Pasithea is also advancing PAS-004 in cancer indications where RAS pathway mutations drive disease. Specifically, the company is studying the drug in tumors driven by BRAF mutations and BRAF fusion events, as well as in ETS2-driven malignancies. The same molecular mechanism — hyperactive MAPK signaling — underlies multiple cancer types, making PAS-004 a platform candidate that could address multiple oncology indications from a single mechanism of action.

The clinical progress to date has been meaningful. Pasithea completed Phase 1 dose-escalation studies in advanced cancer patients, enrolling multiple cohorts with no dose-limiting toxicities observed through eight escalation steps. Treatment-related adverse events were predominantly grade 1–2 in severity — mild to moderate and manageable. Pharmacokinetic data showed a half-life of approximately sixty hours, meaning the drug accumulates slowly and achieves a steady state with relatively stable blood levels, which can simplify dosing schedules and improve tolerability. The company presented preliminary data at medical conferences and initiated a Phase 1/1B expansion cohort focused on adult patients with NF1-associated plexiform neurofibromas.

The pipeline beyond PAS-004.

Pasithea’s second-in-line candidate is PAS-003, targeted at amyotrophic lateral sclerosis (ALS) — a devastating neurodegenerative disease that kills neurons controlling voluntary muscle movement. The mechanism underlying PAS-003 is less fully disclosed in public materials compared to PAS-004, but the program represents the company’s foray into neurodegeneration, a field with few approved treatments and high unmet need.

A third program, earlier in development, is PAS-001, intended to address schizophrenia. The proposed target is complement component 4A (C4A), a protein involved in synaptic pruning during neurodevelopment. Elevated C4 activity has been implicated in schizophrenia pathophysiology; blocking or modulating it is a novel hypothesis in psychiatry. PAS-001 remains a discovery-stage program and is several years from clinical testing in humans.

The financing landscape and cash runway.

Pasithea is pre-revenue — it generates no income from product sales. The company is entirely dependent on equity financing to fund operations, clinical trials, and preclinical research. In May 2025, Pasithea announced a public offering of five million dollars in common stock, a modest raise used to extend cash runway and support ongoing and upcoming clinical studies. Clinical-stage biotech companies routinely require repeated financing rounds to advance through Phase II and Phase III trials, which are more expensive and longer-running than Phase I. The cost and timeline of each financing round are material risks for shareholders; dilution accelerates as new equity is issued.

The regulatory and execution path.

PAS-004’s path forward depends on the outcome of the Phase 1/1B study in NF1 patients. If the data supports efficacy and the tolerability profile remains favorable, Pasithea would likely propose an end-of-Phase 1 meeting with the FDA to outline a Phase II strategy. Phase II studies are designed to assess preliminary efficacy in a larger patient population and to refine the dose and schedule. If Phase II data supports a continued development plan, Phase III trials — the large, controlled studies required for regulatory approval — would follow. The entire timeline from Phase I to potential approval typically spans five to ten years and costs hundreds of millions of dollars.

For the cancer indications (BRAF and ETS2-driven tumors), competitive landscape is relevant. Other MEK inhibitors and targeted cancer therapies have been approved; Pasithea must demonstrate that PAS-004 offers advantages — better tolerability, efficacy, or ease of use — to gain market traction. The company’s macrocyclic architecture is presented as a distinguishing feature, but clinical outcomes will ultimately determine clinical and commercial viability.

How the business depends on upstream and downstream innovation.

Upstream, Pasithea depends on advances in molecular biology and genomics that identified RAS pathway hyperactivation and C4A involvement in disease. The company builds on decades of fundamental research in cancer biology and neuroscience published by university and government laboratories. It must license or design its own assays and tools to identify which patient populations will respond best to its drugs — this is the growing field of companion diagnostics.

Downstream, Pasithea needs access to patient populations, clinical trial sites, and investigators willing to enroll patients in its studies. It also depends on regulatory approval pathways and, ultimately, on pharmaceutical distribution channels and reimbursement systems to get approved drugs to patients. Orphan indications like NF1 may qualify for favorable regulatory pathways (accelerated approval, breakthrough designations) and market exclusivity, reducing competitive pressure once approved. However, the size of the addressable patient population is smaller, constraining peak revenue potential compared to common cancers or major psychiatric indications.

Researching Pasithea as an investment.

Investors should begin with Pasithea’s annual 10-K filing and latest 10-Q quarterly reports (SEC CIK 0001841330). The management discussion section provides color on clinical trial enrollment, data announcements, and near-term milestones. Company press releases announce trial initiations, enrollment completions, and data presentations at medical conferences. Track presentations at oncology (ASCO, ESMO) and neurology conferences where Pasithea presents clinical data. The 10-K risk factors section outlines capital requirements, competitive threats, and regulatory risks. Finally, evaluate the company’s cash balance and the implied runway to key milestones — this determines whether near-term dilution from financing is likely or whether current cash is sufficient to reach a value-inflecting clinical event.